FILING ANALYSIS · THURSDAY, NOVEMBER 12
Century Therapeutics, Inc. IPSC — 8-K: Results of Operations and Financial Condition
neutral
Century Therapeutics reported a cash position of $174.1 million, which is expected to support operations into 1Q 2029, and announced progress on its two potentially transformational programs, CNTY-813 and CNTY-308, with IND submission and clinical trial initiation planned for 4Q 2026 and 2026, respectively.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →